ACTH(4-10) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
== Medical uses == Omacetaxine/homoharringtonine was indicated for use as a treatment for patients with chronic myeloid leukaemia who are resistant or intolerant of tyrosine kinase inhibitors. In June 2009, results of a long-term open label Phase II study were published, which investigated the use of omacetaxine infusions in CML patients. After twelve months of treatment, about one third of patients showed a cytogenetic response. A study in patients who had failed imatinib and who had the drug resistant T315I mutation achieved cytogenetic response in 28% of patients and hematologic response in 80% of patients, according to preliminary data. Phase I studies including a small number of patients have shown benefit in treating myelodysplastic syndrome (MDS, 25 patients) and acute myelogenous leukaemia (AML, 76 patients). Patients with solid tumors did not benefit from omacetaxine.
Former fighters have told the media that the pills helped them overcome their fear. Doctors report that the drug has dangerous side effects, including psychosis and brain damage. According to former fighters, hundreds became addicted to the pills they were given by brigade leaders without knowing what they were taking. Fenethylline use was associated with the rise of jihadist group ISIS. One 19-year-old fighter named Kareem, who said he fought alongside ISIS for more than a year, told CNN in 2014: "They gave us drugs, hallucinogenic pills that would make you go to battle not caring if you live or die." In February 2023, Israel's Ministry of Defense claimed to have thwarted an attempt to smuggle thousands of fenethylline tablets from the West Bank into the Gaza Strip. Hamas claimed it had seized 50,000 fenethylline pills on the border, and claimed Israel was attempting to dope Gaza. Israel has publicly stated that fenethylline was used during the October 7 attacks, but this has been doubted by Caroline Rose, director of New Lines Institute's Strategic Blind Spots Portfolio. Israeli forces said they had found fenethylline-containing tablets, powder, and liquid on the bodies of the attackers. Rose said that she had never seen fenethylline made in liquid form. While precursor chemicals for fenethylline tend to be in powdered form, she said, fenethylline itself is not commonly a powder.
== Mechanotaxis in wound healing == In wound healing, fluid shear stress plays a large role in the mechanotaxis of endothelial cells to the wound site. The inner lining of blood vessels is composed of these endothelial cells, which means that these cells are continuously experiencing fluid shear stress from blood rushing through the vessels. This mechanical stress on the apical side of the endothelial cells leads to integrin signaling, which involves the recruitment of focal adhesion kinase (FAK), Shc, and Crk, and will lead to changes in cell-cell and cell-ECM adhesion. These changes involve lamellipodial protrusions and focal adhesion (FA) formation at the front of the cell, as well as the dismantling of FAs at the rear of the cell, and cause endothelial cells to move in the direction of the flow. Constant laminar flow has been found to improve cell migration in wounds and increases the rate of wound closure.
=== Disaster recovery === Water damage resulting from flooding can result in shrinking, distortion, or staining of plant materials. Unforeseen disasters can occur at any time and disaster recovery planning and materials for herbaria are similar to museums and libraries. Little can be done with burnt specimens and fragmented specimens except to preserve and protect what is left intact. The damage most likely to occur is water damage through natural or man-made flooding, such as roof leakage or fire sprinkler malfunction. Damaged or waterlogged specimens are frozen to delay deterioration and prevent a fungal attack, which gives curators time to evaluate the situation and decide how best to approach the problem.
Sources: en.wikipedia.org
SPR can be used to study the real-time kinetics of molecular interactions. Determining the affinity between two ligands involves establishing the equilibrium dissociation constant, representing the equilibrium value for the product quotient. This constant can be determined using dynamic SPR parameters, calculated as the dissociation rate divided by the association rate.
In 2003 the Americana Music Awards awarded Parsons with the President's Award, which was accepted by his daughter. The 2003 film Grand Theft Parsons stars Johnny Knoxville as Phil Kaufman and chronicles a farcical version of the theft of Parsons' corpse. In 2006, Gandulf Hennig released the documentary Gram Parsons: Fallen Angel. In 2004, Parsons' daughter Polly produced two tribute concerts titled "Return to Sin City: A Tribute to Gram Parsons". Artists included Keith Richards, James Burton, Lucinda Williams, Norah Jones, Dwight Yoakam, John Doe, Steve Earle, Jim Lauderdale, Kathleen Edwards, Jay Farrar, Jim James, Raul Malo, Susan Marshall, and the Sin City All Stars. The concert produced a DVD and 100% of the concerts was donated through the Gram Parsons Foundation to the Musician's Assistance Program (now MusiCares), which aids musicians in crisis. Despite his influence, Parsons has yet to be inducted into the Country Music Hall of Fame. The Gram Parsons Petition Project (later named Gram Parsons InterNational) was begun in May 2008 in support of a drive to induct Parsons into the Country Music Hall of Fame. On September 19, 2008, the 35th anniversary of Parsons' death, it was presented to the Country Music Association (CMA) with the official Nomination Proposal. Parsons was inducted in the Rock and Roll Hall of Fame in 2026 through the influence category. In November 2009, the musical theatre production Grievous Angel: The Legend of Gram Parsons premiered, starring Anders Drerup as Gram Parsons and Kelly Prescott as Emmylou Harris.
Lung fibrosis is a recognized complication of rheumatoid arthritis. It is also a rare but well-recognized consequence of medications used to treat RA such as methotrexate and leflunomide). Caplan's syndrome describes lung nodules in individuals with RA and additional exposure to coal dust. Exudative pleural effusions are also associated with RA.
It has been shown in mice that in certain conditions neutrophils have a specific type of migration behaviour referred to as neutrophil swarming during which they migrate in a highly coordinated manner and accumulate and cluster to sites of inflammation.
=== Muscle fiber growth === Muscle fibers grow when exercised and shrink when not in use. This is due to the fact that exercise stimulates the increase in myofibrils which increase the overall size of muscle cells. Well exercised muscles can not only add more size but can also develop more mitochondria, myoglobin, glycogen and a higher density of capillaries. However, muscle cells cannot divide to produce new cells, and as a result there are fewer muscle cells in an adult than in a newborn.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.